

Noha N Salama

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/636366/publications.pdf>

Version: 2024-02-01

31
papers

1,486
citations

331670
21
h-index

434195
31
g-index

31
all docs

31
docs citations

31
times ranked

1985
citing authors

#	ARTICLE	IF	CITATIONS
1	Tight junction modulation and its relationship to drug delivery [†] . <i>Advanced Drug Delivery Reviews</i> , 2006, 58, 15-28.	13.7	323
2	MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC ^{PK1} cells. <i>Journal of Pharmaceutical Sciences</i> , 2006, 95, 2293-2308.	3.3	130
3	Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. <i>Critical Care Medicine</i> , 2011, 39, 19-25.	0.9	89
4	The role of P-glycoprotein in drug resistance in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 26-33.	1.3	81
5	Synthesis and anticonvulsant activity of enaminones Part 7. Synthesis and anticonvulsant evaluation of ethyl 4-[(substituted phenyl)amino]-6-methyl-2-oxocyclohex-3-ene-1-carboxylates and their corresponding 5-methylcyclohex-2-enone derivatives. <i>European Journal of Medicinal Chemistry</i> , 2003, 38, 49-64.	5.5	79
6	Enaminones: Exploring Additional Therapeutic Activities. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 2509-2531.	3.3	77
7	Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma. <i>Cancers</i> , 2020, 12, 305.	3.7	56
8	Enhanced permeability of molecular weight markers and poorly bioavailable compounds across Caco-2 cell monolayers using the absorption enhancer, zonula occludens toxin. <i>Pharmaceutical Research</i> , 2002, 19, 1680-1688.	3.5	52
9	Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma. <i>Nature Communications</i> , 2020, 11, 6037.	12.8	51
10	Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma. <i>Journal of Controlled Release</i> , 2018, 270, 158-176.	9.9	49
11	The Impact of ¹⁴ C on the Oral Bioavailability of Low Bioavailable Therapeutic Agents. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 199-205.	2.5	45
12	Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1279-1284.	0.7	44
13	Effect of the biologically active fragment of zonula occludens toxin, ¹⁴ C, on the intestinal paracellular transport and oral absorption of mannitol. <i>International Journal of Pharmaceutics</i> , 2003, 251, 113-121.	5.2	40
14	Intradialytic Administration of Daptomycin in End Stage Renal Disease Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1190-1194.	4.5	40
15	The effect of ¹⁴ C on the transport and oral absorption of macromolecules. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 1310-1319.	3.3	36
16	DM27, an enaminone, modifies their vitro transport of antiviral therapeutic agents. <i>Biopharmaceutics and Drug Disposition</i> , 2004, 25, 227-236.	1.9	35
17	The Impact of Pharmacologic and Genetic Knockout of P-Glycoprotein on Nelfinavir Levels in the Brain and Other Tissues in Mice. <i>Journal of Pharmaceutical Sciences</i> , 2005, 94, 1216-1225.	3.3	35
18	Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 922-933.	3.3	35

#	ARTICLE	IF	CITATIONS
19	Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance. <i>Leukemia and Lymphoma</i> , 2017, 58, 2916-2925.	1.3	30
20	Targeting E-selectin to Tackle Cancer Using Uproleselan. <i>Cancers</i> , 2021, 13, 335.	3.7	30
21	Longitudinal Hemodiafilter Performance in Modeled Continuous Renal Replacement Therapy. <i>Blood Purification</i> , 2011, 32, 82-88.	1.8	23
22	Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study. <i>Lancet Oncology</i> , The, 2018, 19, 1082-1093.	10.7	21
23	Multidrug Resistance and Anticonvulsants: New Studies with Some Enaminones. <i>Current Medicinal Chemistry</i> , 2004, 11, 2093-2103.	2.4	19
24	MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma. <i>Blood Cancer Journal</i> , 2016, 6, e399-e399.	6.2	19
25	Preclinical evaluation of the pharmacokinetics, brain uptake and metabolism of E121, an antiepileptic enaminone ester, in rats. <i>Biopharmaceutics and Drug Disposition</i> , 2003, 24, 397-407.	1.9	14
26	Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma. <i>Haematologica</i> , 2016, 101, e307-e311.	3.5	11
27	The influence of enaminones on the transport and oral bioavailability of P-glycoprotein substrate therapeutic agents. <i>International Journal of Pharmaceutics</i> , 2004, 273, 135-147.	5.2	10
28	Combining Drug and Immune Therapy: A Potential Solution to Drug Resistance and Challenges of HIV Vaccines?. <i>Current HIV Research</i> , 2008, 6, 401-410.	0.5	4
29	Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis. <i>Renal Failure</i> , 2019, 41, 118-125.	2.1	3
30	Buparlisib (NVP-BKM-120). <i>Drugs of the Future</i> , 2013, 38, 73.	0.1	3
31	Etanercept Clearance during an in vitro Model of Continuous Venovenous Hemofiltration. <i>Blood Purification</i> , 2009, 28, 348-353.	1.8	2